A pledging conference led by the European Union (EU) has set an initial target of 7.5 billion euros ($8.1 billion) to help end the coronavirus pandemic.
The EU will team up with partners around the globe to hold a pledging initiative, with the aim of raising urgently needed funding to develop effective coronavirus vaccines quickly and build capacity for early manufacturing at scale of diagnostics, vaccines and treatments.
Alongside the funding pledges, the initiative will also aim to secure high-level political commitment to ensuring equitable access to products created to tackle this pandemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze